Glycotope GmbH

https://www.glycotope.com

[Profile January 2025] Glycotope is an asset management and former biotechnology company focused on the management and commercialization of its own license agreements and related assets. [ Profile January 2016 ] Glycotope (www.glycotope.com), founded in 2001 in Berlin, focuses on the development of innovative immune-oncological products for the treatment of various cancer types using their GlycoBody™ and GlycoExpress™ technologies. Glycotope´s GEX™ platform allows glyco-optimization of a variety of fully human glycosylated biopharmaceuticals such as coagulation factors, cytokines, glycoprotein hormones, antibodies, and other protein based biopharmaceuticals by using a toolbox of glyco-engineered proprietary human cell lines that allow for optimization of a whole series of different determining sugars. In addition, the GEX™ platform offers high yield production with unmet quality and reproducibility. Glycotope’s entire human blood coagulation business was recently partnered with Octapharma in an exclusive strategic deal in October 2015. *

	Start	2001-01-01 established
	Group	Glycotope (Group)
	Industry	GlycoExpress™ cellular expression system (GEX™ technology)
	Industry 2	glycomics
	Person	Kollenberg, Henner (Glycotope 201403– Managing Director (CFO) + Eckert Life Science Acclerator before Qonsult Group)
	Person 2	Bracht, Franzpeter (Celonic 201711– COO before Glycotope + Aplagen + Ernst & Young + Kienbaum)

	Region	Berlin
	Country	Germany
	Street	10 Robert-Rössle-Str. Campus Berlin-Buch
	City	13125 Berlin
	Tel	+49-30-9489-2604
		Address record changed: 2023-07-23

Basic data	Employees	D: 101 to 500 (2016-01-07)

		* Document for »About Section«:

		Record changed: 2025-01-19